Health
Sage Therapeutics Jumps on Biogen’s $469 Million Offer
- Deal seen as bargain for Biogen but not game-changer: analysts
- Spike in Sage Therapeutics shares comes after 75% drop in 2024
This article is for subscribers only.
Shares of Sage Therapeutics Inc. surged after Biogen Inc. offered to acquire the neuroscience-focused drugmaker for about $469 million.
The offer of $7.22 a share was disclosed Oct. 10 after US markets closed. The company said it’s reviewing the deal.